Regentatlantic Capital LLC lowered its stake in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 1.2% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 60,476 shares of the medical research company’s stock after selling 754 shares during the period. Thermo Fisher Scientific makes up approximately 1.0% of Regentatlantic Capital LLC’s investment portfolio, making the stock its 24th largest position. Regentatlantic Capital LLC’s holdings in Thermo Fisher Scientific were worth $11,442,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the stock. Rothschild Investment Corp IL boosted its position in shares of Thermo Fisher Scientific by 0.5% during the 3rd quarter. Rothschild Investment Corp IL now owns 70,523 shares of the medical research company’s stock worth $13,343,000 after purchasing an additional 341 shares during the period. Liberty Capital Management Inc. boosted its position in shares of Thermo Fisher Scientific by 2.1% during the 3rd quarter. Liberty Capital Management Inc. now owns 19,579 shares of the medical research company’s stock worth $3,795,000 after purchasing an additional 411 shares during the period. North Star Asset Management Inc. boosted its position in shares of Thermo Fisher Scientific by 2.4% during the 3rd quarter. North Star Asset Management Inc. now owns 48,571 shares of the medical research company’s stock worth $7,461,000 after purchasing an additional 1,126 shares during the period. State of New Jersey Common Pension Fund D boosted its position in shares of Thermo Fisher Scientific by 11.8% during the 3rd quarter. State of New Jersey Common Pension Fund D now owns 95,000 shares of the medical research company’s stock worth $17,974,000 after purchasing an additional 10,000 shares during the period. Finally, Aperio Group LLC boosted its position in shares of Thermo Fisher Scientific by 9.9% during the 3rd quarter. Aperio Group LLC now owns 345,539 shares of the medical research company’s stock worth $65,376,000 after purchasing an additional 31,185 shares during the period. 83.78% of the stock is owned by hedge funds and other institutional investors.

Shares of Thermo Fisher Scientific Inc (NYSE:TMO) opened at $190.17 on Friday. Thermo Fisher Scientific Inc has a fifty-two week low of $139.07 and a fifty-two week high of $201.20. The firm has a market cap of $76,257.22, a price-to-earnings ratio of 20.90, a PEG ratio of 1.74 and a beta of 1.08. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.26 and a quick ratio of 0.81.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 25th. The medical research company reported $2.31 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.24 by $0.07. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. The business had revenue of $5.12 billion for the quarter, compared to analyst estimates of $5.03 billion. During the same period last year, the business earned $2.03 EPS. The company’s revenue was up 13.9% on a year-over-year basis. sell-side analysts anticipate that Thermo Fisher Scientific Inc will post 9.36 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Monday, January 15th. Investors of record on Friday, December 15th will be paid a dividend of $0.15 per share. The ex-dividend date is Thursday, December 14th. This represents a $0.60 annualized dividend and a yield of 0.32%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.19%.

TMO has been the subject of several recent research reports. Zacks Investment Research cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Monday, September 18th. Barclays PLC reissued an “overweight” rating and issued a $215.00 price target (up previously from $200.00) on shares of Thermo Fisher Scientific in a research report on Monday, September 25th. BidaskClub cut shares of Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Argus reissued a “buy” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, August 22nd. They noted that the move was a valuation call. Finally, Morgan Stanley reissued an “overweight” rating and issued a $220.00 price target on shares of Thermo Fisher Scientific in a research report on Wednesday, September 6th. One analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $205.71.

In related news, Director C Martin Harris sold 360 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, August 30th. The shares were sold at an average price of $180.97, for a total transaction of $65,149.20. Following the sale, the director now directly owns 5,312 shares in the company, valued at approximately $961,312.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Seth H. Hoogasian sold 4,140 shares of Thermo Fisher Scientific stock in a transaction on Monday, August 28th. The stock was sold at an average price of $177.80, for a total transaction of $736,092.00. Following the sale, the vice president now owns 25,518 shares in the company, valued at $4,537,100.40. The disclosure for this sale can be found here. Insiders have sold a total of 60,420 shares of company stock worth $11,308,477 over the last quarter. 0.49% of the stock is owned by company insiders.

COPYRIGHT VIOLATION WARNING: This story was first published by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at https://www.watchlistnews.com/thermo-fisher-scientific-inc-tmo-shares-sold-by-regentatlantic-capital-llc/1713516.html.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.